文献速递癫痫

1至36月龄儿童癫痫的药物与饮食治疗:一项系统综述

Pharmacologic and Dietary Treatments for Epilepsies in Children Aged 1-36 Months: A Systematic Review.
PubMed 文献 · Neurology · 2022-10-21

本系统综述检索EMBASE、MEDLINE、PubMed和Cochrane图书馆1999年1月1日至2021年8月19日发表的文献,纳入23项研究(6项随机研究、2项非随机对照研究、15项前后对照研究),评估1至36月龄非婴儿痉挛症癫痫患儿药物与饮食治疗的有效性和危害。所有结论的证据强度均为低。左乙拉西坦使部分婴儿达到无发作(报告无发作的研究中分别为32%和66%),生酮饮食使部分婴儿达到无发作(12%-37%),生酮饮食与改良Atkins饮食均减少平均发作频率,但生酮饮食减少幅度更大(1项随机对照试验报告6个月时生酮饮食发作频率减少71%,而改良Atkins饮食仅减少28%)。

要点

  • 左乙拉西坦使部分婴儿达到无发作(报告无发作的研究中分别为32%和66%),但其他6种药物数据不足。
  • 生酮饮食使部分婴儿达到无发作(12%-37%),生酮饮食与改良Atkins饮食均减少发作频率,生酮饮食减少更多。
  • 所有结论的证据强度均为低,未来研究应进行病因特异性分析并报告以患者为中心的结局。

核心结论

  • 关于1至36月龄非婴儿痉挛症癫痫患儿的药物与饮食治疗,高质量证据很少,所有结论的证据强度均为低。

研究设计与样本

  • 系统综述,检索EMBASE、MEDLINE、PubMed和Cochrane图书馆1999年1月1日至2021年8月19日发表的文献,纳入23项研究(6项随机研究、2项非随机对照研究、15项前后对照研究),评估1至36月龄非婴儿痉挛症癫痫患儿接受29种药物治疗中的1种和/或5种饮食治疗中的1种、报告≥12周有效性结局的研究。

主要发现

  • 左乙拉西坦使部分婴儿达到无发作(报告无发作的研究中分别为32%和66%),但托吡酯、拉莫三嗪、苯妥英、氨己烯酸、卢非酰胺和司替戊醇6种药物的数据不足,无法就有效性得出结论。
  • 左乙拉西坦、托吡酯和拉莫三嗪3种药物很少因不良反应而停药,严重事件罕见。
  • 生酮饮食使部分婴儿达到无发作(12%-37%),生酮饮食与改良Atkins饮食均减少平均发作频率,但生酮饮食减少幅度更大(1项随机对照试验报告6个月时生酮饮食发作频率减少71%,而改良Atkins饮食仅减少28%)。
  • 饮食治疗的不良事件报告不充分。

局限性

  • 关于1至36月龄非婴儿痉挛症癫痫患儿的药物与饮食治疗,高质量证据很少,所有结论的证据强度均为低。
  • 左乙拉西坦以外的6种药物数据不足,无法就有效性得出结论。
  • 饮食治疗的不良事件报告不充分。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Early life epilepsies are common and often debilitating, but no evidence-based management guidelines exist outside of those for infantile spasms. We conducted a systematic review of the effectiveness and harms of pharmacologic and dietary treatments for epilepsy in children aged 1-36 months without infantile spasms. METHODS: We searched EMBASE, MEDLINE, PubMed, and the Cochrane Library for studies published from January 1, 1999, to August 19, 2021. Using prespecified criteria, we identified studies reporting data on children aged 1-36 months receiving pharmacologic or dietary treatments for epilepsy. We did not require that studies report etiology-specific data. We excluded studies of neonates, infantile spasms, and status epilepticus. We included studies administering 1 of 29 pharmacologic treatments and/or 1 of 5 dietary treatments reporting effectiveness outcomes at ≥ 12 weeks. We reviewed the full text to find any subgroup analyses of children aged 1-36 months. RESULTS: Twenty-three studies met inclusion criteria (6 randomized studies, 2 nonrandomized comparative studies, and 15 prestudies/poststudies). All conclusions were rated low strength of evidence. Levetiracetam leads to seizure freedom in some infants (32% and 66% in studies reporting seizure freedom), but data on 6 other medications were insufficient to permit conclusions about effectiveness (topiramate, lamotrigine, phenytoin, vigabatrin, rufinamide, and stiripentol). Three medications (levetiracetam, topiramate, and lamotrigine) were rarely discontinued because of adverse effects, and severe events were rare. For diets, the ketogenic diet leads to seizure freedom in some infants (rates 12%-37%), and both the ketogenic diet and modified Atkins diet reduce average seizure frequency, but reductions are greater with the ketogenic diet (1 RCT reported a 71% frequency reduction at 6 months for ketogenic diet vs only a 28% reduction for the modified Atkins diet). Dietary harms were not well-reported. DISCUSSION: Little high-quality evidence exists on pharmacologic and dietary treatments for early life epilepsies. Future research should isolate how treatments contribute to outcomes, conduct etiology-specific analyses, and report patient-centered outcomes such as hospitalization, neurodevelopment, functional performance, sleep quality, and patient and caregiver quality of life. TRIAL REGISTRATION INFORMATION: This systematic review was registered in PROSPERO (CRD42021220352) on March 5, 2021.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Treadwell JR, Kessler SK, Wu M, et al. Pharmacologic and Dietary Treatments for Epilepsies in Children Aged 1-36 Months: A Systematic Review. Neurology. 2022. PMID: 36270899. doi:10.1212/WNL.0000000000201026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。